Avenue Therapeutics enters worldwide license agreement for ATX-04

Avenue Therapeutics (ATXI) announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 in clinical development for the treatment of Pompe disease. “ATX-04 represents an asset with a favorable risk profile, supported by compelling human clinical data generated at Duke demonstrating functional, biochemical, and molecular benefit in Pompe disease,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics. “This license allows us to advance a differentiated, mechanism-based therapy with the potential to meaningfully enhance outcomes for patients receiving standard-of-care ERT.”